Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

XNCR

+ Watchlist+ Portfolio

Xencor, Inc.

Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$34.50
52-Week Range
$10.38 – $40.60
Market Cap
$2.58B
P/E (TTM)
—
EPS (TTM)
-1.55
Dividend Yield
0.00%
Advanced Metrics
Price/Book
4.59
PEG Ratio
—
Return on Equity
-19.88%
Return on Assets
-11.11%
Gross Margin
-42.50%
Operating Margin
-72.67%
Profit Margin
-58.79%
Current Ratio
6.54
Debt/Equity
0.29
Total Debt
$160.23M
Free Cash Flow
$-96.22M
Revenue Growth
454.90%
Earnings Growth
—
Enterprise Value
$2.34B

Market Snapshot

About

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases. The company uses its proprietary XmAb protein engineering technology platform to create next-generation antibody therapeutics with improved efficacy and safety profiles. Xencor has multiple product candidates in clinical development and partners with leading pharmaceutical companies.